替尔泊肽“头对头”完胜司美格鲁肽 千亿GLP-1市场迎“双寡头”时代

21世纪经济报道
12 May

21世纪经济报道记者季媛媛上海报道GLP-1赛道的竞争越来越激烈,巨头之间抢市场的博弈越来越明显。5月11日,礼来公司公布的SURMOUNT-5研究数据犹如重磅炸弹引爆全球减肥药市场——其新型GLP-1/GIP双受体激动剂替尔泊肽,在减重20.2% VS 13.7%、腰围减少18.4cm VS 13.0cm等关键指标上,全面碾压诺和诺德的司美格鲁肽。根据礼来披露的数据,在该研究的主要终点中,替尔泊...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10